I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation
I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation
Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ:IMAB) offer strong upside potential, according to a Needham analyst.
The I-Mab Analyst: Chad Messer initiated coverage of I-Mab shares with a Buy rating and $75 price target.
The I-Mab Takeaways: I-Mab has an extensive pipeline of innovative assets, including several assets in clinical trials in the U.S. as well as in China, Messer said in a Monday note.
The company has struck four out-licensing partnerships worth up to $3 billion, the analyst said.
I-Mab has also expanded its Chinese business by in-licensing Chinese rights to late-stage assets from biopharma companies such as Ferring, MorphoSys AG (NASDAQ:MOR) and MacroGenics, Inc. (NASDAQ:MGNX), he said.
Related Link: The Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations
I-Mab's lead asset lemzoparlimab, which targets CD47, differentiates itself from other CD47 antibodies by having minimal interaction with RBCs, Messer said.
It is being evaluated in Phase 1 studies as a single agent as well as combo therapy option, the analyst said.
I-Mab's in-licensed asset Felzartamab could mark I-Mab's entry into commercialization in China as early as this year, he said.
"We believe its deep pipeline of proprietary IO assets will allow I-Mab to capitalize on an important, growing sector of oncology."
The company's unique go-to-market strategy in China will likely turn it into a fully integrated Chinese pharmaceutical company with global development expertise, in Needham's view.
IMAB Price Action: At last check, the stock was adding 0.44% to $55.25.
Related Link: Roche Boosts Diagnostics Portfolio With $1.8B Bet On COVID-19 Test Manufacturer GenMark
Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ:IMAB) offer strong upside potential, according to a Needham analyst.
這家在美國上市的中國免疫腫瘤學公司的股票I-Mab(納斯達克：IMAB)提供了強大的上行潛力，根據Needham的一位分析師的説法。
The I-Mab Analyst: Chad Messer initiated coverage of I-Mab shares with a Buy rating and $75 price target.
I-Mab分析師：查德·梅塞爾發起了關於I-Mab股票評級為買入，目標價為75美元。
The I-Mab Takeaways: I-Mab has an extensive pipeline of innovative assets, including several assets in clinical trials in the U.S. as well as in China, Messer said in a Monday note.
I-Mab外賣：梅塞爾在週一的一份報告中説，i-Mab擁有廣泛的創新資產渠道，包括在美國和中國進行臨牀試驗的幾項資產。
The company has struck four out-licensing partnerships worth up to $3 billion, the analyst said.
這位分析師説，該公司已經達成了四項對外許可合作伙伴關系，價值高達30億美元。
I-Mab has also expanded its Chinese business by in-licensing Chinese rights to late-stage assets from biopharma companies such as Ferring, MorphoSys AG (NASDAQ:MOR) and MacroGenics, Inc. (NASDAQ:MGNX), he said.
Related Link: The Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations
I-Mab's lead asset lemzoparlimab, which targets CD47, differentiates itself from other CD47 antibodies by having minimal interaction with RBCs, Messer said.
梅塞爾説，I-Mab的主要資產Lemzoparlimab針對CD47，與其他CD47抗體的區別在於與紅細胞的相互作用最小。
It is being evaluated in Phase 1 studies as a single agent as well as combo therapy option, the analyst said.
這位分析師説，它正在作為單一藥物和聯合治療選擇在第一階段研究中進行評估。
I-Mab's in-licensed asset Felzartamab could mark I-Mab's entry into commercialization in China as early as this year, he said.
他説，i-Mab的授權資產Felzartamab可能標誌着i-Mab最早於今年進入中國商業化。
"We believe its deep pipeline of proprietary IO assets will allow I-Mab to capitalize on an important, growing sector of oncology."
我們相信，其深厚的專有IO資產流水線將使i-Mab能夠利用一個重要的、不斷增長的腫瘤學部門。“
The company's unique go-to-market strategy in China will likely turn it into a fully integrated Chinese pharmaceutical company with global development expertise, in Needham's view.
在李約瑟看來，該公司在中國獨特的入市戰略可能會使其成為一家完全整合的具有全球開發專長的中國製藥公司。
IMAB Price Action: At last check, the stock was adding 0.44% to $55.25.
IMAB價格操作：在最後一次檢查中，該股上漲了0.44%，至55.25美元。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧